Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2024

23-02-2024 | Obesity | Original Contributions

Long-Term Protective Effects and Mechanisms of Gastric Bypass Surgery on the Kidneys in Hypertensive Obese Rat

Authors: Yuan Zhang, Xiangxin Kong, Ke Song, Ming He, Yin Xian, Xing Xie, Junming Cheng, Rubing Bai, Yixing Ren

Published in: Obesity Surgery | Issue 4/2024

Login to get access

Abstract

Objective

Investigate the long-term protective effects of gastric bypass surgery on the kidneys of hypertensive obese rats to better understand the role of gastric bypass surgery in preventing renal injury in humans with hypertension and obesity.

Methods

Compare 6-week-old spontaneously hypertensive rats, including 30 Roux-en-Y gastric bypass (RYGB) and 30 sham operations. Body weight and blood pressure were monitored before and up to 12 months after the operation. Blood lipids, blood creatinine, and blood urea nitrogen were measured. Kidney pathology was assessed using HE staining, while renal fibrosis was observed via Masson staining. Inflammatory indicators were examined by ELISA. The expression of the NLRP3 gene in the kidney was measured using immunofluorescence and western blot, and the changes in key pathways including ASC/IL-1β protein were verified.

Results

RYGB reduced the body weight of hypertensive obese rats and had a protective effect on blood pressure. Additionally, the bypass effectively mitigated renal inflammation and fibrosis. Moreover, RYGB modulated the expression of NLRP3 and prevented kidney damage via the ASC/IL-1 pathway.

Conclusion

This study validates that RYGB effectively attains sustained blood pressure control in hypertensive obese rats and has a potential kidney-protective mechanism via the NLRP3-ASC/IL-1β pathway.

Graphical Abstract

Literature
1.
2.
Ali N, Mohanto NC, Nurunnabi SM, et al. Prevalence and risk factors of general and abdominal obesity and hypertension in rural and urban residents in Bangladesh: a cross-sectional study. BMC Public Health. 2022;22:1707.CrossRefPubMedPubMedCentral
3.
Stompór T, Perkowska-Ptasińska A. Hypertensive kidney disease: a true epidemic or rare disease? Pol Arch Intern Med. 2020;130:130–9.PubMed
4.
Jesky MD, Hayer MK, Thomas M, et al. Do obese individuals with hypertension have more difficult-to-control blood pressure and end organ damage than their nonobese counterparts? J Clin Hypertens. 2015;17:466–72.CrossRef
5.
Leggio M, Lombardi M, Caldarone E, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res Off J Jpn Soc Hypertens. 2017;40:947–63.CrossRef
6.
Kravtsova O, Bohovyk R, Levchenko V, et al. SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats. Am J Physiol Renal Physiol. 2022;322:F692–707.CrossRefPubMedPubMedCentral
7.
8.
Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991–1006.CrossRefPubMedPubMedCentral
9.
Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther. 2023;37:757–70.CrossRefPubMed
10.
Seeley RJ, Chambers AP, Sandoval DA. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 2015;21:369–78.CrossRefPubMedPubMedCentral
11.
Schiavon CA, Bhatt DL, Ikeoka D, et al. Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial. Ann Intern Med. 2020;173:685–93.CrossRefPubMed
12.
Schiavon CA, Ikeoka D, Santucci EV, et al. Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension. Hypertens Dallas Tex. 2019;73:571–7.CrossRef
13.
Nordstrand N, Hertel JK, Hofsø D, et al. A controlled clinical trial of the effect of gastric bypass surgery and intensive lifestyle intervention on nocturnal hypertension and the circadian blood pressure rhythm in patients with morbid obesity. Surgery. 2012;151:674–80.CrossRefPubMed
14.
15.
Chen H, Liu N, Zhuang S. Macrophages in renal injury, repair, fibrosis following acute kidney injury and targeted therapy. Front Immunol. 2022;13:934299.CrossRefPubMedPubMedCentral
16.
17.
Sun Y, Ge X, Li X, et al. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction. Cell Death Dis. 2020;11:1–14.CrossRefPubMedPubMedCentral
18.
Reiss AB, Voloshyna I, De Leon J, et al. Cholesterol metabolism in CKD. Am J Kidney Dis Off J Natl Kidney Found. 2015;66:1071–82.CrossRef
19.
Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015;87:74–84.CrossRefPubMed
20.
21.
22.
Ludwig-Portugall I, Bartok E, Dhana E, et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int. 2016;90:525–39.CrossRefPubMed
23.
Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest. 2013;123:236–46.CrossRefPubMed
24.
Krishnan SM, Ling YH, Huuskes BM, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019;115:776–87.CrossRefPubMed
25.
Kong Y, Feng W, Zhao X, et al. Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney. Theranostics. 2020;10:10415–33.CrossRefPubMedPubMedCentral
26.
Wang S, Chen Y, Han S, et al. Selenium nanoparticles alleviate ischemia reperfusion injury-induced acute kidney injury by modulating GPx-1/NLRP3/Caspase-1 pathway. Theranostics. 2022;12:3882–95.CrossRefPubMedPubMedCentral
Metadata
Title
Long-Term Protective Effects and Mechanisms of Gastric Bypass Surgery on the Kidneys in Hypertensive Obese Rat
Authors
Yuan Zhang
Xiangxin Kong
Ke Song
Ming He
Yin Xian
Xing Xie
Junming Cheng
Rubing Bai
Yixing Ren
Publication date
23-02-2024
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2024
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-024-07108-5

Other articles of this Issue 4/2024

Obesity Surgery 4/2024 Go to the issue

Letter to the Editor

Bariatric Surgery and Remission of Diabetes Mellitus: the Long and Short in the Context of Diabetic Retinopathy

Correction

Correction: Bismuth-Based Therapy: The New Therapy for Obese Patients Undergoing Gastric Bypass Surgery?

Original Contributions

Convincing 10-Year Follow-up Results of the Banded Roux-en-Y Gastric Bypass

Original Contributions

A Prospective Multicenter Standard of Care Study of Outpatient Laparoscopic Sleeve Gastrectomy

Original Contributions

Correlation of T2DM and Anthropometric Measures with Total Small Bowel Length and Its Effects on Diabetes Remission After Bariatric Surgery

Correction

Correction: Concurrent Hiatus Hernia Repair with Bariatric Surgery